Michael Barbella, Managing Editor05.23.22
Truvic Medical Inc. has achieved its first regulatory milestone.
The wholly owned subsidiary of Imperative Care Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Prodigy Thrombectomy System, designed to treat peripheral vascular thrombus.
“We are excited to receive FDA clearance for our first thrombectomy system. We look forward to working with experts in the field to translate Prodigy’s novel design elements and features into superb clinical outcomes,” said Mike Buck, CEO of Truvic. “This represents our first regulatory milestone as part of our strategy to advance multiple programs designed to meet patients’ needs and bring more innovative technologies to the market, faster.”
“Imperative Care and Truvic share a culture of innovation and intense commitment to the needs of patients. I am pleased that these common values continue to help propel our development programs towards elevation of patient care,” said Fred Khosravi, Chairman and CEO of Imperative Care.
Based in Campbell, Calif., Truvic is a wholly owned subsidiary of Imperative Care. Truvic’s technology is designed to redefine peripheral vascular thrombus management by enabling single-session thrombus removal without the use of thrombolytics.
Imperative Care develops the next generation of solutions to address the needs in stroke intervention and peripheral thrombectomy. The company has two FDA 510(k)-cleared product platforms, as well as a stroke technology development pipeline.
The wholly owned subsidiary of Imperative Care Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Prodigy Thrombectomy System, designed to treat peripheral vascular thrombus.
“We are excited to receive FDA clearance for our first thrombectomy system. We look forward to working with experts in the field to translate Prodigy’s novel design elements and features into superb clinical outcomes,” said Mike Buck, CEO of Truvic. “This represents our first regulatory milestone as part of our strategy to advance multiple programs designed to meet patients’ needs and bring more innovative technologies to the market, faster.”
“Imperative Care and Truvic share a culture of innovation and intense commitment to the needs of patients. I am pleased that these common values continue to help propel our development programs towards elevation of patient care,” said Fred Khosravi, Chairman and CEO of Imperative Care.
Based in Campbell, Calif., Truvic is a wholly owned subsidiary of Imperative Care. Truvic’s technology is designed to redefine peripheral vascular thrombus management by enabling single-session thrombus removal without the use of thrombolytics.
Imperative Care develops the next generation of solutions to address the needs in stroke intervention and peripheral thrombectomy. The company has two FDA 510(k)-cleared product platforms, as well as a stroke technology development pipeline.
